Dr. Ben has over 20 years of clinical development expertise including strategic planning, oncology clinical trial design and execution (phase I-IV), and successful BLA/NDA submissions. Under his leadership and direction, several oncology drug candidates were approved including a PD-1 antibody for over seven tumor types, a PARP inhibitor for ovarian cancer, a PD-L1 antibody for urothelial cancer, a proteasome inhibitor for multiple myeloma, a tyrosine kinase inhibitor for renal cancer, and oncolytic virus for head and neck cancers.

Until recently, Dr. Ben served as CMO, Solid Tumors, for BeiGene, a global biotechnology company and previously CMO at BioAtla, a San Diego immunotherapy company. Prior, Dr. Ben was the Global Clinical Lead, Immuno-Oncology at AstraZeneca, leading the approval of durvalumab. Prior to AstraZeneca, Dr. Ben led multiple oncology programs including ixazomib pivotal program that led to an approval in multiple myeloma as well as orteronel and alisertib programs at Millennium Pharmaceuticals, and axitinib which was approved in renal cell carcinoma at Pfizer.

Dr. Ben received his medical degree from Norman Bethune College of Medicine and was a surgical oncologist at Peking Union Medical College Hospital with a post-doc fellowship at California Pacific Medical Center. Dr. Ben earned an MBA from the University of California, San Diego.